Background: Therapeutic drug monitoring (TDM) and model-informed precision dosing
(MIPD) have greatly benefitted from computational and mathematical advances over the …

Optimal pharmacotherapy in pediatric patients with suspected infections requires
understanding and integration of relevant data on the antibiotic, bacterial pathogen, and …

Abstract Model‐informed precision dosing (MIPD) approaches typically apply maximum a
posteriori (MAP) Bayesian estimation to determine individual pharmacokinetic (PK) …

Background Delayed methotrexate elimination can occur in patients undergoing high‐dose
methotrexate cancer treatment. Effectiveness of glucarpidase for rapidly reducing …

Several population pharmacokinetic (PPK) models have been established to optimize the
therapeutic regimen and reduce the toxicity of high-dose methotrexate (HDMTX) in patients …

Methotrexate is used in the treatment of many malignancies, rheumatological diseases, and
inflammatory bowel disease. Toxicity from use is associated with severe morbidity and …

Consensus guidelines recommend use of granulocyte colony stimulating factor in patients
deemed at risk of chemotherapy‐induced neutropenia, however, these risk models are …

Providing maximal therapeutic efficacy without toxicity is a universal goal of rational drug
therapy. However, substantial between‐patient variability in drug response often impedes …

High-dose methotrexate (HD-MTX) is widely used in pediatric acute lymphoblastic leukemia
(ALL) treatment regimens. In this study, we aimed to develop a population pharmacokinetic …

Precision dosing is progressing beyond the conceptual and proof‐of‐concept stages toward
implementation. As the availability of dosing algorithms, tools, and platforms increases, so …